検索
Telix Pharmaceuticals Ltd
TLXウォッチリストに追加
10.560USD
-0.300-2.76%
終値 05/15, 16:00（ET）15分遅れの株価
3.57B時価総額
--直近12ヶ月PER
詳細情報 Telix Pharmaceuticals Ltd 企業名
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltdの企業情報
企業コードTLX
会社名Telix Pharmaceuticals Ltd
上場日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地55 Flemington Road
都市MELBOURNE
証券取引所NASDAQ OMX - NASDAQ BASIC
国Australia
郵便番号3051
電話番号61390933855
ウェブサイトhttps://telixpharma.com/
企業コードTLX
上場日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)
Telix Pharmaceuticals Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Thu, May 14
更新時刻: Thu, May 14
株主統計
種類
株主統計
株主統計
比率
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
他の
99.76%
株主統計
株主統計
比率
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
他の
99.76%
種類
株主統計
比率
Investment Advisor
0.24%
Investment Advisor/Hedge Fund
0.09%
Research Firm
0.06%
Hedge Fund
0.03%
Bank and Trust
0.02%
他の
99.57%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
61
1.47M
0.43%
+326.20K
2025Q4
40
845.28K
0.25%
+354.64K
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Portland Investment Counsel Inc.
266.20K
0.08%
+138.20K
+107.97%
Dec 31, 2025
Lazard Asset Management, L.L.C.
250.52K
0.07%
+135.89K
+118.56%
Dec 31, 2025
Fidelity Management & Research Company LLC
123.57K
0.04%
+5.09K
+4.30%
Dec 31, 2025
Private Advisor Group LLC
46.34K
0.01%
+4.23K
+10.05%
Dec 31, 2025
Marshall Wace LLP
46.66K
0.01%
-1.92K
-3.94%
Dec 31, 2025
JPMorgan Private Bank (United States)
44.49K
0.01%
+19.14K
+75.47%
Dec 31, 2025
Quadrature Capital LLP
36.83K
0.01%
+36.83K
--
Dec 31, 2025
Mariner Wealth Advisors
36.58K
0.01%
+36.58K
--
Dec 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
